Abstract | INTRODUCTION: MATERIALS AND METHODS: At baseline in this cross-sectional substudy of the ASCET trial, 1001 stable CAD patients, all on single aspirin treatment, were classified by the PFA100® method, as having high on- aspirin residual platelet reactivity (RPR) or not. Markers of hypercoagulability, endothelial and platelet activation as related to RPR, were evaluated to explore the potential mechanisms behind high on- aspirin RPR. RESULTS: Altogether, 25.9% (n=259) of the patients were found to have high on- aspirin RPR. S- thromboxane B(2) levels were very low and did not differ between patients having high on- aspirin RPR or not. Patients with high on- aspirin RPR had significantly higher levels of von Willebrand Factor (vWF) (124 vs 100%, p<0.001, platelet count (236 vs 224 × 10(9)/l, p=0.008), total TFPI (68.4 vs 65.5 ng/ml, p=0.005) and ß-thromboglobulin (ß-TG) (33.3 vs 31.3 IU/ml, p=0.041) compared to patients with low on- aspirin RPR. No significant differences between the groups were observed in levels of endogenous thrombin generation (ETP), pro- thrombin fragment 1+2 (F1+2), D-dimer, soluble TF (sTF) or P-selectin (all p>0.05). CONCLUSIONS: The high on- aspirin RPR as defined by PFA100® seems not to be due to increased thrombin activity as evaluated with ETP, sTF, F1+2 or D-dimer. The elevated levels of platelet count, ß-TG, TFPI and especially vWF might be explained by increased endothelial and platelet activation in these patients.
|
Authors | Alf-Åge R Pettersen, Harald Arnesen, Trine B Opstad, Vibeke Bratseth, Ingebjørg Seljeflot |
Journal | Thrombosis research
(Thromb Res)
Vol. 130
Issue 3
Pg. 424-8
(Sep 2012)
ISSN: 1879-2472 [Electronic] United States |
PMID | 22795340
(Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Elsevier Ltd. All rights reserved. |
Chemical References |
- Biomarkers
- Blood Coagulation Factors
- Platelet Aggregation Inhibitors
- Aspirin
|
Topics |
- Adult
- Aged
- Aspirin
(administration & dosage)
- Biomarkers
(blood)
- Blood Coagulation Factors
(analysis)
- Coronary Artery Disease
(blood, drug therapy, epidemiology)
- Dose-Response Relationship, Drug
- Endothelium, Vascular
(drug effects)
- Female
- Humans
- Male
- Middle Aged
- Norway
(epidemiology)
- Platelet Activation
(drug effects)
- Platelet Aggregation Inhibitors
(administration & dosage)
- Platelet Count
- Platelet Function Tests
(statistics & numerical data)
- Prevalence
- Reproducibility of Results
- Sensitivity and Specificity
|